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1 | INTRODUCTION 
The history of pediatric allergology (PA) is 
relatively youthful: in 1984 in Europe, a small 
group of pediatricians founded the first 
European Working Group on
 Pediatric Allergy and
 Immunology—later giving origin to 
ESPACI (European Society of Pediatric 
Allergology and Clinical Immunology).1 ESPACI 
was a response to the need for a subgroup 
within the allergy community focusing on the 
specific unmet needs of infants and children 
developing atopic disease manifestations. 
Until that time, infants and
 children with, or at
 risk of atopic dermatitis,
 food allergy, asthma, allergic rhinitis, 
and/or drug allergy had only the choice of a
 general pediatrician, a
 specialist with a strong
 background in adult
 allergy or a specialist with a special interest but 
no formal training in allergy. The absence of a 
holistic, family- focused approach to allergic 
conditions may have resulted in significant 
additional burden with respect to the 
prevalence and morbidity of atopic diseases in 
the first years of life. 
In the subsequent years, global interest in pediatric allergy research, be 
it basic, translational, and/or clinical, grew and so did the focus on research 
quality. Simultaneously, sessions on pediatric allergy at international 
conferences increased in popularity. In 1990, a dedicated journal, Pediatric 
Allergy and Immunology (PAI), was founded. Now most conferences include 
a considerable number of pediatric sessions. 
A patchwork of differential recognition
 for the discipline of PA developed in Europe 
in accordance with the fact that in some countries, allergology is recognized 
as a full specialty, while in others it is seen as a subspecialty within, for 
example, dermatology, ENT, respiratory medicine and pediatrics. Early 
attempts to harmonize the structure of patient care in this area across 
Europe were unsuccessful until the European Academy of Pediatrics (EAP) 
officially accepted PA as a  certified and acknowledged
 subspeciality in 1999. 
The EAACI- Clemens von Pirquet Foundation (CvP) is a non- profit 
foundation established to promote research and education in pediatric 
allergy. In a sponsored collaboration with the European Academy of Allergy 
and Clinical Immunology (EAACI) Pediatric Section, CvP organized in
 Rome, October 2016, a workshop on the
 future of PA, with a deliberate focus
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 on education, research, and networking/advocacy.
 Invited delegates were the members of the CvP board and senior and junior 
representatives from EAACI Sections and Interest Groups related to the 
focus topic. These delegates represented many countries across Europe and 
CvP additionally invited other representative pediatric allergists. Valuable 
insights were requested from two experts with backgrounds
 in pediatric drug development, including
 immunotherapy. The authors of this paper were all active participants of 
this workshop. The paper represents an official
 statement of CvP and the EAACI Section on 
Pediatrics. 
2 | STATUS QUO IN PEDIATRIC ALLERGOLOGY IN 
EUROPE 
More than two decades after the EAP officially accepted PA as a certified
 and acknowledged subspecialty within
 pediatrics, there are still striking differences
 across Europe in the training pathways for
 doctors seeing children with allergic disease(s). The types of doctors 
currently engaged in PA in Europe can be outlined as followed: 
1. Those fully trained in general pediatrics with (extra) dedicated time in 
allergy. These are pediatricians who have a special interest in allergy, 
and the allergy-dedicated training duration varies among
 countries, for example, in UK where
 this is known as SPIN (special interest) in 
allergy and tends to be for those who wish to work
 in secondary service with dedicated allergy
 clinics. 
2. Those trained where PA is a subspecialty within pediatrics, namely 
through an (integrated) general pediatrics (core) training and full 
specialist allergy training program leading to accreditation as pediatric 
allergists. In these countries, PA is regarded as a full
 (sub)specialty, for example, Sweden, Turkey,
 Denmark, and UK. Subspecialty pediatric allergy training 
in the UK is a 3-year program approved by the Royal College of 
Paediatrics and Child Health, and subspecialty accreditation is awarded 
by the General Medical Council; this is the
 usual route to working in a
 tertiary or academic UK allergy unit.
 In Turkey, after 5 years of
 general pediatric specialty, the pediatric immunology and 
allergy training are independent 3-year full specialty program. Of note, 
in some countries, pediatricians that have been dedicated to seeing 
allergic children for a specified sufficient period of time have been 
granted accreditation as pediatric allergists (such as in Spain with 
pediatricians consulting allergic children for 5 years or more). 
3. Those who have completed core training in adult general medicine and, 
in some cases, a short or equal period of pediatrics, followed  
by a combined clinical training in child and adult allergy. These are 
allergists and allergy is considered as a full (sub)specialty. 
Representative examples of countries implementing this training 
system are Greece, Portugal, Spain, France, and Romania. 
4. A fourth setting exists where allergy is not regarded as specialty, and the 
onus is on the individual physician to train themselves to feel confident 
in seeing children with allergic problems. This may happen in the case 
of adult ENT and ophthalmology surgery specialists in
 Germany, for example, and the
 Workshop agreed this situation is suboptimal for both 
the patients and the physicians involved. This setting includes many 
clinicians appointed to posts in the 1990s and 2000s. 
It is also vital to acknowledge
 and consider the experienced non- medical 
healthcare professionals (HCP) who support and add value to the optimal 
diagnosis and management of allergy in children. Countries differ in the 
training and utilization of allied HCP within the allergy teams. Specialist 
nursing and dietetic clinics already occur in some allergy centers in the UK 
and Scandinavia.2 However, to date, the authors are unaware of an 
accredited curriculum and certification in allergy in Allied Health, although 
ratified 2- year training programs for asthma or eczema exist. This issue
 could and should be addressed with the
 appropriate stakeholders. 
All delegates of the workshop have endorsed
 the concept that optimal care of children with allergic 
diseases is delivered by pediatricians who have received dedicated training 
in allergy, or allergists who have received dedicated training in pediatrics. 
Therefore, the proposed way forward is for only these specialists to be 
accredited to consult children with allergic diseases in the near future. 
Nonetheless, the panel acknowledges the
 idiosyncrasies of each country’s specialty training 
programs. Respect is given to the fact that there are allergists with
 general adult medicine as their background
 who have been seeing allergic children routinely, 
especially in light of the absence of pediatric allergists in their country. On 
this basis and for the time being, doctors currently engaged in PA who have 
not undergone pediatric training but can demonstrate
 the necessary skills and competencies can still 
be considered to be accredited as pediatric allergologists, akin to
 the ‘grandfather’ clause that allows
 continuing practice for those appointed/in post before formal 
accreditation processes were established. In countries where
 PA is an acknowledged specialty or
 where there are EAP- certified PA centers,
 accreditation can take place through a formal 
application of the doctor to the PA national society or PA center of the 
country, respectively. The role of the ETC- PA in individual certification of 
European Specialists and center certification has been a
 key to the development of PA
 in Europe. Although not a legal license to 
practice, this certification is an important asset to an individual CV, 
particularly in countries where PA does not officially exist and may also help 
to give visibility to the subspeciality and to influence its recognition. It is also 
a prerequisite to accredit training centers, as teachers must be qualified and 
recognized as such. After international visitation and accreditation, all 
involved centers to date (6 in Spain and 7 in Sweden) agreed that this 
initiative led to an improvement in teaching quality, clinical quality, planning 
of training, and training of techniques. 
Notably, it is up to national
 bodies to acknowledge subspecialties and to 
define the rules for training center accreditation and subspecialist 
certification in their countries. These rules should ideally be similar all over 
Europe. In countries where a given subspecialty is not recognized, the 
international certification of centers may play a crucial role in promoting the 
visibility and final recognition of this field as a specialized area of medicine 
in that country. 
3 | EDUCATION ACCORDING TO THE EAP 
EUROPEAN PAEDIATRIC ALLERGOLOGY TRAINING 
PROGRAMME 
The European Paediatric Allergology Training Programme was firstly 
approved in 1999 and revisions made until a consensus syllabus was 
approved in the end of 2016.3 It is one of the subspecialist training programs 
in tertiary care pediatrics, defined by the Tertiary Care Group of EAP, itself 
the Paediatric section of the European Union of  
Medical Specialists (Union Européenne des Médecins Spécialistes— UEMS). 
Based on this program, pediatric allergists are expected to practice
 their skills and apply their expertise within
 the framework of a specialized tertiary care unit. These 
specialists will also have the commitment of training general pediatricians 
and pediatricians with interest in PA. 
According to this training program, all doctors practicing PA require a 
prescribed and nationally accredited basic training in general pediatrics, as 
set out by many National Training Authorities, and the recommended
 European Common Trunk Syllabus, approved by the
 EAP- UEMS. This program stipulates 3 years minimum in general pediatrics, 
serving as a prelude to PA. In some countries, a clinical training period of 24- 
month full- time employment in PA is considered adequate, but others 
require longer for accreditation. 
Nevertheless, the content or competencies demonstrated and not the 
length of education a priori should be the basis of PA subspecialty 
certification. A precise training syllabus3 is detailed in the European 
Pediatric Allergology Training Programme. This is structured in modules, 
each containing training requirements in a specific area, expertise,
 or skill. Simultaneous training in several
 modules is possible, according to local service and training 
configurations. Training can be completed with modules acquired in several 
different training centers, with at least one named, trainer- recognized 
primary center. Immunology is regarded as an add- on module and in some 
countries a separate subspecialty. Immunodeficiencies are not officially 
included in the PA curriculum. 
Competency- based assessment, as an
 adjunct to knowledge assessment and portfolio 
completion, is an important aspect of evaluation. Several countries have 
recently reformed their postgraduate medical education, and competencies 
should be evaluated throughout the training period. PA trainees are 
encouraged and required to keep a contemporaneous
 written logbook of patients they have seen,
 together with procedures conducted, and the therapeutic interventions 
instigated and followed up. This will constitute part of their portfolio. 
Research training is considered an essential aspect of the PA curriculum. 
Furthermore, attendance at International Congresses and giving 2 to 3 
presentations in such meetings are highly recommended. 
4 | PEDIATRIC ALLERGY EXAMS 
A knowledge- based assessment is
 desirable and preferably included in a national final examination. 
EAACI is currently organizing a modification of the EAACI Knowledge Exam 
which offers an official knowledge certificate for
 allergists/clinical immunologists. This modification will 
lead to a specific certification for pediatric allergists on a European and 
global level. This will impact on the implementation of structured pediatric 
allergy care in all European countries. In addition, it could
 offer an optional replacement for the
 knowledge- based assessment of PA national certification, 
provided it is accepted by the relevant national authority. These EAACI 
Exams on PA are anticipated to help the harmonization of education and 
exchange of young doctors in the PA field
 across Europe. Moreover, this kind of
 certificate will be of value for national validation. While the examination 
may not replace the established training and rules for the specialty foreseen
 by each nation, this kind of
 certificate will be of value as an
 additional qualification. 
5 | NETWORKS FOR PEDIATRIC ALLERGISTS 
ACROSS EUROPE 
In order to meet the needs of children and families with allergic disease(s), 
the pediatric allergist is highly encouraged to develop several networks
 (Figure 1). Engaging with different groups
 facilitates education, training, clear communication, creates the 
opportunity to develop shared pathways for patients, as well as for 
recruiting potential experts in the field. 
5.1 | Multidisciplinary team pediatric allergy clinics 
Pediatric subspecialty services are becoming increasingly multidisciplinary. 
Proposed members of the allergy multidisciplinary team (MDT) include 
pediatric allergists, specialist nurses, dietitians, and psychologists.
 The ideal is to have a “one-
 stop shop” model where children and their families 
attend pediatric allergy clinics composed of MDT members. The
 skillset of the MDT is diverse and
 may overlap. Generally: medical clinicians have overarching 
responsibility for patients; dietitians guide exclusion diets and 
reintroductions as well a facilitate optimal nutrition; and nurses usually 
support food and drug challenges, perform allergy tests, as well as ensure 
emergency plans are in place. In addition, nurses most often liaise with 
schools in order to ensure the child is safe in the community— this can 
involve visiting schools or training school nurses to recognize and treat 
allergic reactions. The roles of MDT members are expanding; many centers 
are developing nurse- led and dietetic- led clinics where clinically 
appropriate, which increases access for patients. This creates opportunities 
for focused and practical education and quality- of-
 life improvements. The “one- stop shop”
 model makes holistic patient care more efficient.
 MDTs could be even broader and include liaison with 
allergy- related pediatric subspecialties, such as ENT, respiratory, 
gastroenterology, dermatology, and ophthalmology teams. There are 
centers which have set up joint clinics where patients are assessed by 
subspecialists simultaneously—the provision of this service mostly depends 
on local resources. 
5.2 | Primary care 
In many European countries, the majority of patients with allergic disease(s) 
will consult first with their primary caregiver (eg, general practitioner [GP] 
in the UK, general pediatrician in Switzerland). Remarkably, one-
 third of all UK GP consultations
 in 2007 were due to allergic diseases.
 Although pediatric allergy networks and national societies 
are engaged and annual meetings well attended, they infrequently
 involve the primary caregiver. Establishing links
 with primary caregivers will create opportunities—for education and 
training, as well as to facilitate prompt referrals and shared care for
 patients. Regional networks can be a way
 of involving primary care in continuous education and pediatric 
allergists must reach out to primary care where time for training might be 
scarce. Other initiatives include EAACI primary care symposia during EAACI 
meetings and adaptation of an EAACI masterclass in PA for primary care 
physicians. 
5.3 | Regional networks 
In some European countries, regional networks are
 increasingly popular, as they facilitate education and information 
dissemination among pediatric allergy MDT across the region. Tertiary 
centers tend to coordinate meetings, with attendance from MDT members 
from secondary care hospitals and occasionally by primary care. There is an 
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opportunity to collect regional data, for example, for asthma, food 
challenges, and creating regional guidelines, such as standardized food 
challenge, referral pathways for drug allergy, or even to conduct audits. 
Most importantly, there is an opportunity to discuss cases, be it simple or 
complex, among experts from the tertiary center. We strongly support
 the constitution of regional clinical networks
 led by trained and experienced pediatric allergists, and 
including physicians and allied health professionals involved in the care of 
allergic children and adolescents. Clinical and research
 networks also need to focus on strategic 
partnerships and collaboration with adult colleagues to better understand 
how to support each other’s needs and to align activities. 
5.4 | International networking 
Well- established PA centers can offer great support to centers in other 
countries where PA is emerging. Short, as well as longer term, visits to both
 sides of the network should be
 encouraged, not only for trainees, but also for 
established professionals. Moving to a country with a higher cost
 of living is a major problem impairing
 the ability to take up a training or 
sabbatical position. Fostering and supporting the activities of pediatric 
allergists in their local centers as well as exchanges across clinical and
 research networks allow growth of expertise and
 sharing of ideas. With this in mind, it has been noted that fellowship 
grants and training opportunities should be available to those who are still 
or have just completed their training but no longer qualify for junior 
membership, for example, at EAACI. Similarly, consultants in post have 
expressed the wish to learn from other centers in a way which realistically
 allows useful networking and cross-
 pollination of ideas. 
Certification of PA centers for training through ETC- PA should be 
encouraged. Certified centers will be identified as resource centers for 
exchange and will testify to a high level of clinical care. In addition, it is
 important to acknowledge centers that provide
 excellent clinical or research exposure to specific aspects of 
PA, to avoid oversubscription of well- known centers,
 and to engage and develop new centers
 of excellence. 
5.5 | Medical students and pediatric trainees 
Provision of allergy teaching within the undergraduate curriculum is 
variable throughout Europe. Medical schools might allocate a most 
commonly restricted time for undergraduate allergy teaching. It is vital that 
undergraduate medical students are exposed to the specialty to foster the 
interest and enthusiasm of individuals interest and enthusiasm in 
individuals who may become future specialists in the field. Similarly, allergy 
training should be offered to pediatric trainees in order to generate interest 
and recruitment into PA. 
5.6 | Social media and modern communication Apps 
Digital tools are useful for communication among healthcare professionals
 who provide pediatric allergy services. In Turkey,
 for instance, a closed WhatsApp group was created to facilitate case 
discussions among HCP who deal with children with allergic disease(s). 
Facebook is a popular platform for
 patients/families to interact. Similarly, Twitter has been 
gaining increasing interest the last years in the medical community as its 
users can: 
1. follow a Journal’s latest articles (eg, through the hashtag #PAI_ Journal
 for all PAI papers) or many
 of the key messages presented in 
Meetings’ sessions (eg, via #EAACI2017 for all twitter posts on the EAACI 
Congress 2017), 
2. participate in Twitter discussions meant either for professionals (eg, via 
#AboutAllergy for twitter discussions organized by EAACI) or patients 
and lay public (eg, through #AllergyReady). 
These potentially powerful learning and communication tools also 
require some guidance for optimal clinical conduct and governance and 
need to be identifiably distinct and separate from ungoverned
 patient/parent sites which are not backed
 by science and medical expertise. For all information in 
the public domain, strict patient confidentiality has to be adhered to, in 
accordance with, local trust guidelines. EAACI has an annex dedicated to the 
proper use of social media by HCP as part of the EAACI code of ethics.4 In 
time, there is likely to be a
 need for formal education on this included
 as part of training. 
5.7 | Media 
Pediatric allergology is a topic of wide interest to the media. Aside from 
social media, some may find it useful to engage with the traditional media 
of communication in order to ensure seamless dissemination of the correct 
information. Effective and coordinated communication can avoid negative 
publicity due to fatalities, near- misses from food anaphylaxis, for example, 
or may be better presented as a result. Additionally, effective liaison with 
and through the media should be communicated at national and EU level 
aiming at promoting the prioritization of allergic diseases. 
5.8 | Patient organizations 
Pediatric allergists engage with and support professional patient 
organizations to further support families. This creates an educational 
opportunity—ensuring that scientific information is understood by patients 
and families for better outcomes and that our patients’ needs are met and 
their priorities held paramount. 
5.9 | Pharmacists 
In addition to their knowledge of
 medicines, pharmacists also provide advice, information, 
and treatment for a number of chronic conditions and play a vital part in 
health promotion and disease prevention initiatives. Pharmacists are 
educated to support patients manage medicines and their side effects 
effectively5 while they contribute to improved patient adherence. 
Therefore, they are important liaisons for pediatric allergists and can further 
contribute to increased awareness of allergic diseases. 
6 | CURRENT STATE AND FUTURE OF PEDIATRIC 
ALLERGY RESEARCH IN EUROPE 
Recent years have seen significant advances in our understanding
 of allergenic pathophysiology and tolerance
 induction. Work is underway to assess the generalizability 
and feasibility of practical recommendations for optimal public health 
impact. There are also several new therapeutic drug options becoming 
available which need pediatric trials. With research opportunities in basic, 
translational, clinical, epidemiologic, and drug trials, more trainees and 
trained specialists are needed. It is certainly an exciting time to be a 
pediatric allergologist! 
Our challenge now is to develop a clear strategic approach to scientific 
excellence to across our member base and to ensure and enhance the 
relevance of European pediatric research in allergy (Table 1).  
Several key areas for potential investment
 include: 
TABLE 1 Key areas for investment in pediatric allergy research 
• Prevention of allergic disease(s) 
• Better diagnostic tools and evidence-based management 
• New drug development and trials, more streamlined, ethical, and 
relevant processes and regulation 
• Innovation and technology for better personalized clinical care, public 
health, and research tools. Improved strategic communication and 
collaboration with public health, economists, and regulatory bodies and 
the public and press 
• Fostering networks for research 
6.1 | Prevention of allergic disease(s) 
Research is ongoing for the prevention of eczema, food or respiratory 
allergy, or required in the epidemiology of allergy; genetics, immunology, 
molecular, and cellular mechanisms of the allergic immune response and 
for drugs suitable for children. 
Basic science research is underrepresented in pediatric medicine, and 
this should be strategically highlighted to the EU and national funding 
agencies. Recent studies have made significant inroads into understanding 
the pathophysiology of tolerance induction, as well as the specifics of 
primary food allergy prevention. These messages necessarily lead to further 
epidemiologic and clinical translational and intervention studies. Pediatric 
medicine is a fertile research ground for cohort studies but, for reasons not 
fully explored in the remit of this paper, it
 has been historically weak on trials and
 this is due to change. 
6.2 | Diagnostic tools and management in PA 
Better child and young person- centric diagnostic tools are needed to avoid 
misdiagnosis or unnecessary positive challenges. In vitro diagnostics appear 
promising with respect to predicting positive food or drug
 challenges, but there is much work
 to be done in relation to easier 
and accurate diagnosis of non- IgE allergy. Research in diagnostic 
biomarkers also needs to take into
 account if, and how, the potentially different 
physiology of children is important at different age ranges. Accurate
 and earlier diagnostics for allergic diseases
 and risk of development would help prevent missing 
the window of opportunity and thus optimize chances of primary and 
secondary prevention. 
At the same time, effective research in drug allergy in children— and 
more effective means of navigating difficult and slow processes related to 
drug research in children—is much needed. An example of important public 
health intervention resulting from such research is the removal of 
pholcodine from over the counter products, such as children cough syrups. 
The wide- scale reduction in exposure to this allergen means potentially 
fatal anaphylactic reactions to neuromuscular blocking drugs
 may be prevented. 
Allergen- specific immunotherapy (AIT), first described in 1908, has 
recently been rejuvenated with respect to oral, epicutaneous, sublingual, or 
subcutaneous modalities for food allergy as well as with the introduction of 
peptides instead of whole extracts against allergic rhinitis.6 More child- 
friendly and better access to AIT is required, as is better standardization and 
training. Ongoing surveillance of adverse side effects and tolerability as 
regards quality of life is imperative. 
6.3 | New drug development and trials for pediatric 
safety and efficacy 
It is known that drugs for
 neonates, infants, and very young children need to 
be reviewed with respect to drug absorption, distribution, metabolism, and 
excretion and the implication on drug usage, especially dose.
 However, for older children, despite acknowledgment
 that brain maturation may take up
 to 25 years, pharmacological or
 metabolic characteristics may be as for adults. Of note though, EU pediatric 
regulation requires a pediatric investigation plan (PIP) for every new drug
 as a condition for marketing approval. 
It is important to discuss that AIT products in the EU were exposed to
 two key legislations in 2007/2008:
 a requirement for PIP submission, and the 
German therapy allergen ordinance.7 The latter made it mandatory for 
manufacturers to register every AIT product, despite being in
 use for decades. As Germany is the
 largest market for AIT products, this affected all 
allergen AIT manufacturers in Europe. More than a hundred PIPs were 
submitted in short time, resulting finally in a massive study program 
proposed to involve 58 five- year double- blind randomized placebo- 
controlled allergen AIT safety and efficacy trials with several hundred 
participants. The deadline for these studies is December 2031. While 
aspects of current AIT products on the market need
 appropriate study and review, there is
 concern that the requirement for participation of 
thousands of children and adolescents potentially leaves children
 at risk of unnecessary morbidity and,
 those assigned to placebo groups, at risk
 of progression or march of allergic
 disease. 
Many clinical specialists are unaware of this issue and would rationally 
question the necessity of trials which would hold up the ability of children 
to benefit from medications that have been proven to be of benefit in 
adults. The PIP system is due for discussion in the EU parliament, and it is 
hoped that representatives from PA and EAACI will raise their voice together 
with those from other pediatric  specialties8 to review
 the EMA’s position which risks suffocating
 pharmaceutic innovation. 
6.4 | Innovation and technology 
Innovation and technology for better personalized clinical care, public 
health, and research tools is a growing and rapidly changing field. EAACI is 
already cognisant of this fact and a mobile health taskforce has
 been created to evaluate and develop the
 organization’s approach. The promise is of more effective tools to monitor 
patients, to educate patients or professionals, and to improve adherence. 
These potential benefits need to be rigorously evaluated to assess the true 
impact and whether or not the mobile health or digital tools are indeed 
effective in improving education, adherence, and self- efficacy in the 
management of allergic diseases. Collaboration and engagement with 
primary care and public health as well as extra pediatric groups, such as 
health economists and appropriately skilled tech
 expertise, will be required to inform
 assessment and trials. 
6.5 | Improved strategic communication and 
collaboration 
Improved strategic communication and collaboration is related to public 
health, economists, regulatory bodies, the lay public, and the press. 
Pediatric allergists must be strong advocates for their patients. 
6.6 | Fostering networks for research 
The need for the development of pan- European registries to facilitate 
research and care was highlighted in an EAACI statement by Professor 
Papadopoulos et al. in 2012.9 As an example of the valuable information a 
registry can carry, the European Anaphylaxis Registry has recently provided 
significant epidemiologic information on the eliciting factors of anaphylaxis 
in children and adolescents.10 
At the same time, a key area
 for development is the identification
 of clinical centers involved or interested in
 the care and research work in PA. They will 
represent a platform for research collaboration and communication
 in the form of registers or clinical
 networks. Currently, these arise on an ad
 hoc basis for studies, but maintained
 networks with established leads and contact
 points are likely to facilitate research integration 
into clinical practice both in the study phase and at implementation
 of new guidance. A drug allergy network
 exists currently. 
7 | PLANNING AHEAD 
A strategic plan to enhance PA as a specialty should focus on its unique
 strengths and aim to minimize its
 weaknesses. A focus on pediatrics and on 
primary, secondary, and tertiary prevention also favors health promotion 
and cost- effectiveness of EU health systems. PA requires a defined 
expertise, while immense research and increased interest are
 taking place in this field. PA, as
 a pediatric subspecialty, has the gratifying ability to intervene 
early and to improve health and quality of life of allergic children, 
adolescents, and their families, over the long term. Nonetheless, pediatric 
allergology is currently not recognized in
 all countries, and there is a lack
 of visibility and awareness of the benefits of implementing this 
subspecialty. The wide diversity between nations and the differential 
approach of health implementation priorities will continue to be a basis
 of weaknesses for PA. 
Opportunities are emerging from the rising number of allergic children, 
and PA has the possibility to modulate disease progression and, potentially, 
to provide primary prevention. Allergy at all ages is still under- recognized 
as a health issue by other specialties, as well as by government bodies, and 
this has adverse implications for health and research budgets. 
Journals publishing on pediatric allergy should inspire and demand 
quality and timely research by ensuring high acceptance standards, critical 
expert reviews, rapid turnaround times, and electronic publication. 
To ensure a positive future for
 groundbreaking pediatric allergy research, the roadmap ahead 
should provide mentorship and support for juniors, as well as for 
established researchers. The appropriate signposting of existing support 
and resources including specific expertise, mentoring, and research post 
and funding opportunities is essential. The role and importance of national 
member organizations are the keys to the
 grassroots support and growth of these ideas
 and the promotion of and for pediatrics in allergy clinical 
guidance, training, research, and policy. EAACI and other Europe- wide or 
international organizations need to provide strategic support to pediatric 
inclusion in these spheres and EAACI already actively support the inclusion 
of meaningful pediatric recommendations in their
 guideline work. 
8 | CONCLUSION 
Pediatric allergology as a subspecialty is being better recognized, and a 
universally acceptable standard for training and accreditation is being 
refined. Original research should be promoted, as well as outstanding 
review articles for key topics. The rapid
 publication of meeting reports, with the aim to 
provide both an overview and a discussion of the latest advances presented 
in pediatric research would be welcomed. 
The role for EAACI and similar organizations worldwide who wish to 
prioritize the agenda for PA needs to include the following: broadening of 
national representation, lobbying for recognition across stakeholder
 countries, the free movement of
 realistically funded specialists in training, and accurate and 
well-c ommunicated reports on the economic benefits of disease control 
and prevention for commissioners, policy, and funding bodies. These efforts 
ultimately have one aim—to improve the health and quality of life of 
children predisposed to and suffering with allergic disease. 
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